Purpose Survival after amputation for melanoma is short; however, rare long-term survivors are reported. The mechanism for durable systemic tumor control in patients with regional failure is not known. To explore whether systemic tumor immunity may be implicated, tumor and circulating immune responses were examined in a patient who survived disease-free 14 years after hip disarticulation. Methods A 71-year-old female with extensive regional metastases of melanoma in the left lower extremity underwent amputation for palliative reasons. Tumor was collected at surgery, and blood was collected during follow-up. Tumor sections were evaluated for lymphocytic infiltration and NY-ESO-1 expression by immunohistochemistry. Cellular immune responses to defined tumor antigens were evaluated by ELISPOT assay, and antibody responses to a panel of tumor antigens were assayed by ELISA.
Introduction
Amputation of a major extremity is rarely performed for management of melanoma. When performed, it is typically with palliative intent and is associated with short survival [1, 2] . However, some long-term survivors have been reported [2, 3] . The mechanism for failure of locoregional disease control without progression to distant metastases remains a mystery. Presented here is a case of long-term survival in a patient who underwent palliative amputation with extensive loco-regional metastatic melanoma of the leg including gross blood vessel involvement. Investigation of serum and tumor from this patient demonstrated a systemic response to a melanoma tumor antigen, NY-ESO-1, but a seemingly paradoxical paucity of tumor-infiltrating lymphocytes in tumor samples. Though these findings may be coincidental, spontaneous systemic tumor immunity with failure of local immune response represents one possible explanation for the clinical course described. If spontaneous systemic tumor immunity contributed to the long-term survival of the patient described, this phenomenon may have potential implications for cancer immunotherapy and surgical decision-making.
Case report
In 1983, a 60-year-old white female presented with a pigmented lesion on the skin of her anterior tibia. This lesion was biopsied, and histologic examination suggested that the lesion was most consistent with an in-transit metastasis. No primary lesion was found. She was initially treated with wide excision of the lesion, but suffered multiple regional recurrences and in-transit metastases of the left lower extremity, also treated with resection and inguinal lymph node dissection, with metastases in 4 of 8 femoral lymph nodes. She was subsequently treated with multiple rounds of chemotherapy including DTIC, BCNU, and cisplatin, as well as BCG injections to in-transit metastases.
The patient was first evaluated at our institution in 1994 at age 71, 11 years after initial diagnosis and subsequent to the treatments listed above. On evaluation, she presented with extensive regionally metastatic melanoma of the left lower extremity, with confluent dermal metastases of nonpigmented melanoma covering the vast majority of the skin surface of her left lower extremity, associated with lymphedema and cellulitis. A metastatic workup was undertaken with computed tomography, magnetic resonance imaging, and bone scan, demonstrating no evidence of disease beyond the left lower extremity. However, magnetic resonance imaging of the affected extremity revealed many soft-tissue nodules in the skin and subcutaneous fat (Fig. 1) . This imaging underestimates the clinical extent of disease, which grossly consisted of a continuous sheet of nodular tumor tissue involving all the skin of the anterior aspect of the left lower extremity up to a level about 3 cm below the inguinal ligament. During this period of evaluation, the patient was admitted for multiple episodes of septic thrombophlebitis and was maintained on Coumadin therapy. Given the presence of deep venous thrombosis, the extent of disease, the recent infectious complications, and her age, she was not considered a candidate for IL-2 or for isolated limb perfusion.
Following evaluation of possible limb perfusion therapy, the patient continued to require serial hospitalizations for cellulitis of the affected extremity, septic thrombophlebitis, and gastrointestinal bleed related to anti-coagulation therapy. Given these complications and her inability to remain liberated from inpatient care, palliative hip disarticulation was offered to the patient, to remove the affected Fig. 1 Radiologic appearance of extensive regional metastasis of melanoma. MRI image prior to amputation demonstrating marked edema, skin thickening consistent with cutaneous tumor, and tumor nodules throughout the left lower extremity, compared with the normal right lower extremity extremity, which she accepted. Every attempt was made to obtain a clear margin during the operation; however, during ligation of the femoral vein, a suspicious lymph node was noted at the proximal resection margin. That node was excised. It was not feasible to re-excise to a higher margin. The patient had an uneventful postoperative recovery. Pathologic evaluation of the extremity demonstrated a confluent tumor mass of melanoma overlying the anterior leg and multiple subcutaneous nodules composed of highly atypical melanocytes, some with epithelioid features. Frequent intranuclear pseudoinclusions and mitotic figures were identified. Perineural invasion was not seen; however, vascular invasion was found present in multiple areas, involving both large and small blood vessels. Representative sections are seen in Fig. 2 , demonstrating vascular invasion with intraluminal tumor (Fig. 2) . Multiple femoral lymph nodes, including the resected lymph node at the proximal margin, were positive for melanoma as well.
The patient was followed up by her oncologist (WWG) every 3 months, with imaging at least yearly. She remained active and clinically free of melanoma recurrence until the last follow-up. Ten years after her hip disarticulation, the patient experienced vaginal bleeding and was found to have poorly differentiated serous papillary carcinoma of the uterus, treated with hysterectomy and bilateral salpingo-oophorectomy. Subsequently, she developed pulmonary nodules, retroperitoneal adenopathy, and supraclavicular adenopathy. The supraclavicular nodes were biopsied and found to contain metastatic serous papillary carcinoma. Thus, she was treated for metastatic uterine cancer, with taxol and carboplatin; however, her disease progressed and she expired of widely metastatic serous papillary uterine cancer at age 85, with no evidence of melanoma recurrence 14 years following her hip disarticulation and 25 years after diagnosis of melanoma of unknown primary origin.
Methods
To identify factors that may have played a role in the long survival of this patient, despite the poor prognosis associated with her presentation, banked peripheral blood mononuclear cells (PBMC) and tumor were evaluated for evidence of tumor immunity and tumor antigen expression.
Immunohistochemical assessment
Paraffin-embedded metastatic tumor samples from the patient's amputation were obtained and assessed for lymphocytic infiltrate and expression of cancer antigens. Representative sections were double-stained for CD45 and CD31. Single stains were also performed for CD4, CD8, CD20, CD68, NKp46, and peripheral node addressin (PNAd). Tissue sections were deparaffinized and then rehydrated using xylene and a graded alcohol series. For CD31/CD45 double staining, antigen retrieval was performed in Dako Target Retrieval Solution, pH 9 (Dako North America, Carpinteria, CA) at 100°C for 20 min. Sections were then incubated for 60 min at room temperature with antibodies to CD31 (1:100, Dako) and CD45 (1:200, Dako). CD31 was detected using an alkaline phosphatase kit (AK-5002, Vector Laboratories, Burlingame, CA) and was visualized with Vector Blue. CD45 was detected using the horseradish peroxidase kit (MP-7402, Vector) and was visualized with VIP, Purple. Dako Target Retrieval Solution, pH 9, was also used with stains for CD4, CD8, and NKp46. Vector's Target Retrieval Solution, pH 6, was used for CD20, CD68, and PNAd. Following antigen retrieval at 100°C for 20 min, sections were incubated for 60 min at room temperature with antibodies to CD20 (1:200), CD8 (1:200), and CD68 (1:50) from Dako, CD4 (1:120, Vector), NKp46 (1:60, R&D, Minneapolis, MN), or PNAd (1:25, Pharmingen, San Jose, CA). Vector's ImmPRESS (Peroxidase) kits were used for CD4, CD8, CD20, CD68, and NKp46. The peroxidase was developed by 3-amino-9-ethylcarbazole (AEC substrate kit: Vector) or 3, 3 0 -diaminobenzidine (DAB substrate kit: Dako); Vector's Alkaline Phosphatase ABC kit was used for PNAd, with Vector Red substrate. Slides were counterstained with Gill's hematoxylin (Vector). Tissue control slides included lymph nodes and/or tonsils. Negative control slides were obtained by omitting the primary antibodies.
Based on the CD45/CD31 double stain, the degree of immune cell infiltrate was scored and assigned an immunotype as has been previously described, based on the architectural patterns of those infiltrates relative to intratumoral blood vessels [4] . Additional sections of tumor were stained for NY-ESO-1 expression, using mAb E978, generated in our laboratory previously. Preceding the primary application, slides underwent antigen retrieval by heating for 30 min (98°C) in a buffer solution (hipH solution, Dako, Carpinteria, CA). E978 was applied overnight at 5°C. As a secondary system, the Powervision kit (Leica Microsystems, Buffalo Grove, IL) was used. Diaminobenzidine (DAB, Biogenex, San Ramon, CA) served as a chromogen. Slides were counterstained with Gill's hematoxylin. Testis with intact spermiogenesis was used as a positive control tissue.
Antigen recognition and serology
To investigate the possible role of cell-based systemic tumor immunity, direct interferon-gamma (IFN-c) ELI-SPOT assays, using pools of peptides, were performed on PBMC isolated from cryopreserved blood collected 6 and 12 years after amputation. Peptide pools were composed of 15-mers, with 11 amino acid overlap derived from 8 immunogenic tumor antigens (gp100, MAGE-A1, MAGE-A3, MAGE-A4, Melan-A/MART1, NY-ESO-1, tyrosinase, and tyrosinase-related protein 2), a positive control (CMV pp65 peptide pool), and one negative control (HIVgag).
These pools were purchased from JPT Peptide Technologies GmbH, Berlin, Germany. A mixture of short viral peptides (CEF peptide pool) was used as another positive control, and HIV gag peptide was used as a negative control. Titration assays demonstrated 4 lg/mL final concentrations to be optimal for detection of response with pools of 15-mer peptides; this concentration was used for the assay data presented. Methods for direct ELISPOT have been reported [5] . Assays were completed in triplicate and averaged for each pool.
Banked samples of plasma and serum from the whole blood, stored at -80°C, were available at 3 time points: 1.75, 5.25, and 6 years after amputation (plasma July 1996, and Feb 2000; serum, Oct 2000). A series of fulllength recombinant well-defined tumor antigen proteins (including NY-ESO-1, LAGE-1, p53, ATF2, MELAN-A, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, SSX1, SSX2, SSX4, SOX2, CT7, CT10, CT45, CT46, CT47, XAGE-1, GAGE2, PASD1, CSAG2, TRAG3, ERG, NXF2, SAGE1, ACTL8, CXorf48, UBQLN2) and a control protein (dihydrofolate reductase [DHFR]) were used to coat plates and to measure specific serum antibody levels in ELISA as described previously [6] . In some experiments, 68-mer synthetic long overlapping peptides from NY-ESO-1 were used as the coating antigen. Plasma/sera were tested in fourfold serial dilutions, and bound IgG reactivity was detected using alkaline phosphatase (AP)-labeled goat anti-human IgG (polyclonal antisera; Southern Biotech). A reciprocal titer was estimated from optical density readings of serially diluted plasma/serum samples as described [6] . Negative control sera from healthy individual and positive control sera for each antigen from cancer patients were included in all assays. The plasma samples had been diluted with media to approximately 39 their original volume during initial collection; this was accounted for in testing and calculation of antibody titers. The serum was of full concentration. To be considered significant, reciprocal titers had to be >100. Assays were repeated in at least 3 independent experiments with reproducible results.
Results

Immunohistochemical assessment
The CD45/CD31 double stain revealed a paucity of tumor-infiltrating lymphocytes (Fig. 3a, c) ; perivascular cuffing was seen only very rarely (Fig. 3b, d ). This was most consistent with immunotype A [4] . Representative sections are displayed in Fig. 3 . Sections of a tumor nodule stained for other immune cell markers revealed no significant infiltrate of CD4
? or CD8 ? T cells, B cells (CD20), or NK cells (NKp46); CD68 staining highlighted endothelial cells [7] , but macrophages were not evident (Fig. 4a) , There was a peritumoral focus of immune cells that included a dense aggregate of B cells, and adjacent T cells (CD4 ? and CD8 ? ), small numbers of NK cells, and a prominent macrophage population; there were prominent vessels in this aggregate (Fig. 4b ), but they did not stain for PNAd (not shown). Each of these cell types were also represented among the rare perivascular cells elsewhere in the tumor, but these were not organized (data not shown).
Staining for NY-ESO-1 demonstrated intense positivity (3?) of 50-75 % of the tumor cells, with some areas of heterogeneous staining. Representative sections are displayed in Fig. 5 .
T-cell reactivity to melanoma antigens
In the IFN-gamma ELISPOT assays, high T-cell reactivity was observed to the NY-ESO-1 peptide pool (65-fold higher than the negative control), but consistent reactivity to the other peptides was not detected (Fig. 5c) . Similar findings were evident in both PBMC samples from about 6 and 12 years after surgery.
Antibodies to melanoma antigens
High antibody titers were identified at all three time points (1.75-6 years after surgery) to NY-ESO-1 (titers 501-1,324) and less strongly to homolog LAGE-1 (titers 22-153, Table 1 ). Reactivity was not observed to p53, ATF2, MELAN-A, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, SSX1, SSX2, SSX4, SOX2, CT7, CT10, CT45, CT46, CT47, XAGE-1, GAGE2, PASD1, CSAG2, TRAG3, ERG, NXF2, SAGE1, ACTL8, CXorf48, UB-QLN2, or DHFR (data not shown). Reactivity to NY-ESO-1 was further evaluated by testing for antibodies to long peptide fragments of that protein: dominant reactivity was observed to ESO pep1 (amino acid residues 1-68), with low reactivity to ESO pep2 (amino acid residues 57-124).
Discussion
Long-term survival after palliative extremity amputation for melanoma is dismal. Few cases have been reported in the recent literature. In a series of 15 patients undergoing palliative amputation, no patient survived longer than 33 months [2] . In patients undergoing limb amputation for melanoma with curative intent, 5-year survival estimates range from 0 to 37 % [1, 2, 8] . Conversely, there are rare reports of relatively long-term survival, including one patient reported by the Danish Amputation Registry who died 10 years after amputation, of unrelated cancer [3] . Such long-term survivors present a biologic paradox, where failure to combat disease regionally is coincident with unknown mechanisms preventing distant metastasis. This is especially apparent in our patient, in whom the ELISPOT data from PBMC 6 years after surgery (c); reactivity is based on a direct ELISPOT assay, with pools of overlapping 15-mer peptides from each protein listed on the X-axis. Positive controls include reactivity to CEF peptides (63.5 ? 2.5 spots) and CMV pp65 peptide pools (341 ? 2.5 spots). Error bars represent standard deviation among triplicate wells. These data are representative of several repeat experiments never developed systemic metastases and lived more than a decade, to die of another cause at advanced age. Spontaneous control of systemic dissemination of melanoma naturally raises a question of whether the patient's immune response to melanoma played a role. Surprisingly, there was a striking lack of lymphocyte infiltrate in the regional tumor specimen. Brisk lymphocytic infiltration has been associated with lower rates of metastasis and death from primary melanomas [9, 10] , and this phenomenon has also been demonstrated in colorectal cancer and ovarian cancer [11] [12] [13] . In metastatic melanoma, patients with diffuse lymphocytic infiltrate (immunotype C) demonstrated improved outcomes, whereas those with few lymphocytes or limited to perivascular infiltration (immunotypes A and B) had lower rates of long-term survival [4] . The CD45/ CD31 staining pattern of the tumor in our patient would indicate an immunotype A lesion, further decreasing her expected survival. Another interesting finding is the peritumoral aggregate of immune cells, which contained a B-cell area and associated T cells. This resembles a lymph node, though the lack of PNAd differentiates it from a true normal lymph node. It may represent a tertiary lymphoid organ. Similar structures have been identified in association with melanoma metastases having good prognosis [14] and in association with lung cancers with improved prognosis [15] , though the precise mechanism is not entirely clear.
We postulate that a systemic immune response to melanoma antigens may have prevented distant spread, but may have failed to control disease locally because circulating antitumor effector T cells were unable to infiltrate established metastases. This hypothesis is supported by the finding of T cell and antibody reactivity to NY-ESO-1, which was durable 2-12 years after amputation of the limb and was evident many years before the development of endometrial cancer. NY-ESO-1 is a cancer/testis antigen that is expressed in 32-47 % of metastatic melanomas including the patient presented here [16, 17] . NY-ESO-1 has been investigated as a target in immune therapies and has generated interest due to the findings that NY-ESO-1 antibodies and T-cell responses correlate with clinical benefit in patients treated with CTLA4 blockade [18] .
Melanoma metastasis and systemic progression are governed by many factors, of which antitumor immunity is just one. The data presented here do not address other factors that may have contributed to the observed clinical course, and these data are limited by their retrospective nature and by the quantity and timing of specimens available. Nevertheless, the findings support the speculation that systemic tumor immunity may have played a role in the patient's good outcome. It is possible that spontaneous antitumor immunity may contribute to systemic protection and clinical tumor control after surgery. Further study is warranted to explore whether spontaneous antitumor immunity may help to identify patients who may benefit from the surgical therapy of advanced melanoma. 
